Gastrointestinal Stromal Tumors News and Research

RSS

Small intestine tumors linked to improved survival in adolescents and young adults

Gastrointestinal stromal tumors are tumors that arise is the wall of the digestive tract, and most often occur in the stomach or small intestine. Though more common in later in life, GISTs can occur in adolescents and young adults under 40 years old as well.

19 Jan 2017

Researchers identify new gene fusions and mutations linked to subset of GIST patients

In recent years, researchers have identified specific gene mutations linked to gastrointestinal stromal tumors (GIST), which primarily occur in the stomach or small intestine, with 5,000 to 6,000 new cases per year in the United States.

16 Dec 2016

Researchers discover Hedgehog signaling pathway is key to formation of gastrointestinal stromal tumors

Researchers at University of California San Diego School of Medicine and Mayo Clinic provide the first evidence that the Hedgehog signaling pathway is central to the formation of gastrointestinal stromal tumors (GIST), which are frequently driven by the KIT oncogene.

1 Nov 2016

Expanding the potential of existing cancer therapies: an interview with Dr Mark Rutstein

Cancer remains a leading cause of death worldwide, and the global cancer burden is expected to increase by 70 percent over the next two decades.

14 Jul 2016

Moffitt study reports that liver metastases have different sensitivities to radiation therapy

Radiation is a commonly used therapeutic option to treat liver metastases, with the majority of tumors maintained under control after one year. However, some patients do not respond as well to radiation treatment, and the factors that predict patient outcomes are unclear. Moffitt Cancer Center researchers report that liver metastases have different sensitivities to radiation therapy based on the location of the primary tumor.

13 Apr 2016

Certain malignant gastrointestinal stromal tumors more deadly than previously reported

Researchers at University of California, San Diego School of Medicine have determined that certain gastrointestinal stromal tumors (GISTs) are more deadly than previously reported in medical literature. Findings are published online in the Journal of Gastrointestinal Surgery.

6 Apr 2016

Molecular imaging and radiochemistry: the importance of instrumentation. An interview with Professor Björn Wängler

Interview conducted with Professor Björn Wängler, Professor for Molecular Imaging and Radiochemistry from Heidelberg University.

From Bruker BioSpin Group 4 Feb 2016

Kolltan announces presentation of data from KTN0158 preclinical study in mast cell tumors at ESMO 2015

Kolltan Pharmaceuticals, Inc. today announced the presentation of data from a preclinical study evaluating KTN0158 in dogs with spontaneous mast cell tumors. KTN0158 is a proprietary, humanized anti-KIT IgG1 monoclonal antibody drug candidate being developed as a potential therapy for cancer and mast cell-related diseases.

28 Sep 2015

Overview of Blueprint Medicines' kinase drug discovery strategy published in JCI

Blueprint Medicines today announced that the Journal of Clinical Investigation published an overview of the Company's kinase drug discovery and development strategy. The publication underscores Blueprint Medicines' focus on identifying novel genomically defined disease drivers and the use of novel chemistry from its proprietary compound library to craft highly selective kinase inhibitors for new and difficult-to-drug kinase targets.

11 May 2015

Low doses of imatinib drug can push immune system to combat bacterial infections

Low doses of the anti-cancer drug imatinib can spur the bone marrow to produce more innate immune cells to fight against bacterial infections, Emory researchers have found.

1 Apr 2015

New study finds increase in use of adjuvant systemic therapy for gastrointestinal stromal tumors

A new study finds that the use of adjuvant systemic therapy for localized gastrointestinal stromal tumors (GISTs ) has significantly increased over time and that patients treated with the therapy have better survival than those treated with surgery alone.

3 Mar 2015

UCSD researchers define epidemiology of gastrointestinal stromal tumors

Researchers at the University of California, San Diego School of Medicine have, for the first time, clearly defined the epidemiology of gastrointestinal stromal tumors (GIST), which occur primarily in the lining of the stomach and small intestine.

8 Oct 2014

ARIAD reports data from Iclusig Phase 2 trial in adult patients with gastrointestinal stromal tumors

ARIAD Pharmaceuticals, Inc. today announced, for the first time, data from its Phase 2 trial of Iclusig (ponatinib) in adult patients with refractory metastatic and/or unresectable gastrointestinal stromal tumors (GIST).

2 Jun 2014

ARIAD provides update on corporate developments, reports Q1 2014 financial results

ARIAD Pharmaceuticals, Inc. today reported financial results for the first quarter of 2014, including revenue from sales of Iclusig® (ponatinib) and licensing agreements. The Company also provided an update on corporate developments.

7 May 2014

Old FDA-approved drugs may hold promise for treatment of rare, drug-resistant cancer

University of Pittsburgh Cancer Institute (UPCI) scientists have shown that old drugs might be able to do new tricks.

14 Feb 2014

Blueprint Medicines closes $25 million Series B financing

Blueprint Medicines today announced the completion of a $25 million Series B financing. The oncology-focused investor, Nextech Invest Ltd., led the round, which also included founding investors Third Rock Ventures and Fidelity Biosciences as well as public investors Biotech Value Fund, L.P., Casdin Capital, LLC and other undisclosed investors.

7 Jan 2014

Scientists prevent cell sleep to reduce chance of tumor recurrence

An international research team led by University of Pittsburgh Cancer Institute (UPCI) scientists discovered that by preventing cancer cells from entering a state of cellular sleep, cancer drugs are more effective, and there is a lower chance of cancer recurrence.

2 Aug 2013

ARIAD Pharmaceuticals initiates ponatinib Phase 2 trial in adult patients with metastatic GIST

ARIAD Pharmaceuticals, Inc. today announced the initiation of the Phase 2 trial of Iclusig (ponatinib) in adult patients with metastatic and/or unresectable gastrointestinal stromal tumors.

11 Jun 2013

Bayer receives FDA approval for Stivarga to treat advanced gastrointestinal stromal tumors

The U.S. Food and Drug Administration today expanded the approved use of Stivarga (regorafenib) to treat patients with advanced gastrointestinal stromal tumors (GIST) that cannot be surgically removed and no longer respond to other FDA-approved treatments for this disease.

26 Feb 2013

Novartis receives FDA approval for Ph+ acute lymphoblastic leukemia

The U.S. Food and Drug Administration today approved a new use of Gleevec (imatinib) to treat children newly diagnosed with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).

27 Jan 2013